Mesoblast (ASX:MSB) Other Operating Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
40 GF Score
Price A$2.04
! 4 Warning Signs
View Full Analysis

What is Mesoblast Other Operating Expense?

Mesoblast ASX:MSB -1.92% 40 Other Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 40/100. The stock has 4 warning signs investors should review.

Mesoblast's Other Operating Expense for the three months ended in Dec. 2025 was A$0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Mesoblast's annual Other Operating Expense increased from Jun. 2023 (A$-5.22 Mil) to Jun. 2024 (A$-1.24 Mil) and increased from Jun. 2024 (A$-1.24 Mil) to Jun. 2025 (A$0.61 Mil).

Mesoblast Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Mesoblast's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Other Operating Expense Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.04 0.76 -5.22 -1.24 0.61

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:MSB
40GF Score
Mesoblast Ltd ASX:MSB
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Other Operating Expense of A$0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Mesoblast and its competitors.
Is Mesoblast's Other Operating Expense too high?
Mesoblast's current Other Operating Expense is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Other Operating Expense compare to VRTX and REGN?
Mesoblast's Other Operating Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Mesoblast and its competitors. Mesoblast's current Other Operating Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Other Operating Expense of A$0.00 Mil. The current Other Operating Expense is A$0.00 Mil. Mesoblast's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Other Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
40GF Score

Get the complete analysis for ASX:MSB

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.04
Price